213 related articles for article (PubMed ID: 16997171)
1. Response monitoring of neoadjuvant therapy using CT, EUS, and FDG-PET.
Sloof GW
Best Pract Res Clin Gastroenterol; 2006; 20(5):941-57. PubMed ID: 16997171
[TBL] [Abstract][Full Text] [Related]
2. The accuracy of endoscopic ultrasonography with fine-needle aspiration, integrated positron emission tomography with computed tomography, and computed tomography in restaging patients with esophageal cancer after neoadjuvant chemoradiotherapy.
Cerfolio RJ; Bryant AS; Ohja B; Bartolucci AA; Eloubeidi MA
J Thorac Cardiovasc Surg; 2005 Jun; 129(6):1232-41. PubMed ID: 15942562
[TBL] [Abstract][Full Text] [Related]
3. Does FDG-PET add information to EUS and CT in the initial management of esophageal cancer? A prospective single center study.
McDonough PB; Jones DR; Shen KR; Northup PG; Galysh RL; Hernandez A; White GE; Kahaleh M; Shami VM
Am J Gastroenterol; 2008 Mar; 103(3):570-4. PubMed ID: 17941963
[TBL] [Abstract][Full Text] [Related]
4. Staging in oesophageal cancer.
Plukker JT; van Westreenen HL
Best Pract Res Clin Gastroenterol; 2006; 20(5):877-91. PubMed ID: 16997167
[TBL] [Abstract][Full Text] [Related]
5. 18F-FDG PET and 18F-FDG PET/CT for assessing response to therapy in esophageal cancer.
Krause BJ; Herrmann K; Wieder H; zum Büschenfelde CM
J Nucl Med; 2009 May; 50 Suppl 1():89S-96S. PubMed ID: 19380406
[TBL] [Abstract][Full Text] [Related]
6. The role and clinical value of EUS in a multimodality esophageal carcinoma staging program with CT and positron emission tomography.
Pfau PR; Perlman SB; Stanko P; Frick TJ; Gopal DV; Said A; Zhang Z; Weigel T
Gastrointest Endosc; 2007 Mar; 65(3):377-84. PubMed ID: 17321235
[TBL] [Abstract][Full Text] [Related]
7. Detection of interval distant metastases: clinical utility of integrated CT-PET imaging in patients with esophageal carcinoma after neoadjuvant therapy.
Bruzzi JF; Swisher SG; Truong MT; Munden RF; Hofstetter WL; Macapinlac HA; Correa AM; Mawlawi O; Ajani JA; Komaki RR; Fukami N; Erasmus JJ
Cancer; 2007 Jan; 109(1):125-34. PubMed ID: 17146785
[TBL] [Abstract][Full Text] [Related]
8. Impact of fluorodeoxyglucose PET on the management of esophageal cancer.
Salavati A; Basu S; Heidari P; Alavi A
Nucl Med Commun; 2009 Feb; 30(2):95-116. PubMed ID: 19194210
[TBL] [Abstract][Full Text] [Related]
9. Utility of 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography and positron emission tomography/computed tomography imaging in the preoperative staging of head and neck squamous cell carcinoma.
Roh JL; Yeo NK; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
Oral Oncol; 2007 Oct; 43(9):887-93. PubMed ID: 17207656
[TBL] [Abstract][Full Text] [Related]
10. Role of positron emission tomography in the (re-)staging of oesophageal cancer.
Westerterp M; Van Westreenen HL; Sloof GW; Plukker JT; Van Lanschot JJ
Scand J Gastroenterol Suppl; 2006; (243):116-22. PubMed ID: 16782630
[TBL] [Abstract][Full Text] [Related]
11. EUS, PET, and CT scanning for evaluation of pancreatic adenocarcinoma.
Mertz HR; Sechopoulos P; Delbeke D; Leach SD
Gastrointest Endosc; 2000 Sep; 52(3):367-71. PubMed ID: 10968852
[TBL] [Abstract][Full Text] [Related]
12. PET monitoring of therapy response in head and neck squamous cell carcinoma.
Schöder H; Fury M; Lee N; Kraus D
J Nucl Med; 2009 May; 50 Suppl 1():74S-88S. PubMed ID: 19380408
[TBL] [Abstract][Full Text] [Related]
13. [Diagnosis of esophageal cancer using positron emission tomography].
Tamura K; Yoshikawa K; Tsujii H; Murata H
Nihon Geka Gakkai Zasshi; 2002 Apr; 103(4):325-30. PubMed ID: 11993219
[TBL] [Abstract][Full Text] [Related]
14. Adenocarcinomas of the esophagus: response to chemoradiotherapy is associated with decrease of metabolic tumor volume as measured on PET-CT. Comparison to histopathologic and clinical response evaluation.
Roedl JB; Colen RR; Holalkere NS; Fischman AJ; Choi NC; Blake MA
Radiother Oncol; 2008 Dec; 89(3):278-86. PubMed ID: 18701180
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of 18-FDG PET/CT and EUS-defined tumour characteristics in patients with oesophageal cancer.
Chan DS; Fielding P; Roberts SA; Reid TD; Ellis-Owen R; Lewis WG
Clin Radiol; 2013 Apr; 68(4):352-7. PubMed ID: 22981727
[TBL] [Abstract][Full Text] [Related]
16. Utility of response evaluation to neo-adjuvant chemotherapy by (18)F-fluorodeoxyglucose-positron emission tomography in locally advanced esophageal squamous cell carcinoma.
Makino T; Miyata H; Yamasaki M; Fujiwara Y; Takiguchi S; Nakajima K; Higuchi I; Hatazawa J; Mori M; Doki Y
Surgery; 2010 Nov; 148(5):908-18. PubMed ID: 20378140
[TBL] [Abstract][Full Text] [Related]
17. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer.
Swisher SG; Maish M; Erasmus JJ; Correa AM; Ajani JA; Bresalier R; Komaki R; Macapinlac H; Munden RF; Putnam JB; Rice D; Smythe WR; Vaporciyan AA; Walsh GL; Wu TT; Roth JA
Ann Thorac Surg; 2004 Oct; 78(4):1152-60; discussion 1152-60. PubMed ID: 15464463
[TBL] [Abstract][Full Text] [Related]
18. [Which is the best monitoring study (tumor marker, computed tomography or 18F-fluoro-2-deoxy-D-glucose positron emission tomography) to evaluate efficacy of chemotherapy on unresectable pancreatic cancer ?].
Kobayashi N; Fujita K; Fujisawa T; Takahashi H; Yoneda M; Abe Y; Inamori M; Kirikoshi H; Kubota K; Saito S; Nakajima A
Gan To Kagaku Ryoho; 2008 Jan; 35(1):65-70. PubMed ID: 18195530
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic and prognostic value of 18F-FDG PET/CT for patients with suspected recurrence from squamous cell carcinoma of the esophagus.
Guo H; Zhu H; Xi Y; Zhang B; Li L; Huang Y; Zhang J; Fu Z; Yang G; Yuan S; Yu J
J Nucl Med; 2007 Aug; 48(8):1251-8. PubMed ID: 17631554
[TBL] [Abstract][Full Text] [Related]
20. The evolving role of PET-CT in the management of esophageal cancer.
Chuang HH; Macapinlac HA
Q J Nucl Med Mol Imaging; 2009 Apr; 53(2):201-9. PubMed ID: 19293768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
